The KCNG2 antibody targets the potassium voltage-gated channel subfamily G member 2 (KCNG2), a protein encoded by the *KCNG2* gene. This gene belongs to the voltage-gated potassium (Kv) channel family, specifically the Kv6 subfamily, which modulates the electrical activity of cells by regulating potassium ion flow. KCNG2 functions as a "silent" subunit, unable to form functional homotetrameric channels on its own but capable of assembling with pore-forming alpha-subunits (e.g., Kv2 family members) to alter their gating kinetics, voltage dependence, or trafficking. This interaction influences cellular excitability in tissues such as the brain, heart, and smooth muscle. KCNG2 expression is detected in the central nervous system, pancreatic islets, and certain cancers, suggesting roles in neuronal signaling, insulin secretion, and tumor biology. Antibodies against KCNG2 are essential tools for studying its expression patterns, protein-protein interactions, and functional contributions to physiological or pathological processes. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence. Dysregulation of KCNG2 has been implicated in neurological disorders, cardiac arrhythmias, and cancer progression, making it a potential therapeutic target. Researchers rely on KCNG2-specific antibodies to validate gene-editing outcomes, assess tissue distribution, and explore its mechanistic roles in disease models. Validation of antibody specificity via knockout controls or peptide blocking is critical due to high homology among Kv channel subunits.